Sun Pharma Settles Patent Litigation With Celgene Over Cancer Drug
Sun Pharma announces settlement of patent litigation for generic Revlimid in the U.S.
Sun Pharmaceutical Industries Ltd. has settled a patent litigation for a generic of blood cancer pill with innovator Celgene Corp., a wholly-owned subsidiary of Bristol Myers Squibb.
Celgene will grant Sun Pharma a licence to its patents required to manufacture and sell, subject to the U.S. Food and Drug Administration approval, certain limited quantity of lenalidomide capsules—a generic of Revlimid—in the U.S. sometime after March 2022, India’s largest drugmaker said in an exchange filing.
The licence will also allow Sun Pharma to manufacture and sell an unlimited quantity of generic lenalidomide capsules in the U.S. beginning Jan. 31, 2026.
As a result of the settlement, all Hatch-Waxman litigation between Sun Pharma and Celgene, regarding the Revlimid patents will be dismissed, the filing said.
Previously, at least three Indian drugmakers — Cipla Ltd., Natco Pharma Ltd. and Dr. Reddy’s Laboratories Ltd. — and the U.S.-based Alvogen had settled patent litigations for Revlimid with Celgene.
Shares of Sun Pharma were trading 0.41% lower as of 2 p.m. on Tuesday compared with a 0.45% gain in the benchmark Nifty 50.